Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape

Authors

  • Sita Bhella, MD Princess Margaret Cancer Centre, Toronto, ON

DOI:

https://doi.org/10.58931/cht.2023.2342

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by excessive production and improper function of plasma cells. This results in an abnormal high M protein or immunoglobulin protein which can result clinically in lytic lesions, anemia, renal dysfunction, and hypercalcemia. Multiple myeloma is not curable; however, there has been a rapid evolution of therapies in the past two decades, leading to an improvement in overall survival (OS).

Author Biography

Sita Bhella, MD, Princess Margaret Cancer Centre, Toronto, ON

Dr. Sita Bhella completed her medical school training at University of Western Ontario. She completed her internal medicine and hematology residency at University of Toronto, and subsequently completed a Leukemia and Allogeneic Bone Marrow Transplant Fellowship at Princess Margaret Cancer Center in Toronto. She completed a Master’s degree in Education at the Ontario Institute for Studies in Education. Dr. Bhella joined Princess Margaret Cancer Centre in 2019, as an Assistant Professor and a clinician in quality improvement and innovation. Dr. Bhella has an interest in malignant hematology, particularly lymphoma, myeloma, autologous stem cell transplantation, and cellular therapy.

References

NORD. Multiple myeloma. Website: https://rarediseases.org/rare-diseases/multiple-myeloma. 2/6/2023. Accessed date: August 1, 2023.

Elsfeld C, Kajuter H, Moller L, Wellmann I, Shumilov E & Stang A. Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany. BMC Cancer, 2023; 23,317.

Gandhi UH, Cornell RF, Lakshman A, Gahvari Z, McGehee E, Jagosky MH, Gupta R, Varnado w, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK & Costa LJ. Outcomes of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy. Leukemia, 2019; 33(9): 2266-2275.

Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, W C J van de Donk N, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broil A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H & Moreau P. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards care in patients with relapsed and/or refractory multiple myeloma. 2022. Leukemia, May, 36(5):1371-1376.

Dana Farber Cancer Institute. CAR T-cell Therapy. dana-farber.org. Accessed August 1, 2023.

Hansen DK, Sidana S, Peres LC, Leitzinger CC, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Arash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL & Patel KK. 2023. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience from the Myeloma CAR T Consortium. Journal of Clinical Oncology, April 10; 41(11):2087-2097.

Munshi NC, Anderson LD, Shah N, Madder D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P & Yakoub-Agha I. 2021. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, February 25, 2021; 384:705-716.

Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deal A, Htut M, Lesokhin A, Munshi NC, O’Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Changwei Z, Pacaud L, Madduri D, Jakubowiak A, Lin Y &Jagannath S. 2022. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2 Year Follow Up. Journal of Clinical Oncology, 41:6, 1265-1274.

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Mounzer A, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O’Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T & Jagannath S. 2021. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. The Lancet, 398, 10297:314-324.

Davis J, McGann M, Shockley A & Hashmi H. 2022. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma. Expert Review of Hematology, 15 (6): 473-475.

San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernandez de Larrea C, Martinez-Lopez J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh T, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ & Einsehe H. 2023. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. New England Journal of Medicine, 389:335-347.

Rendo MJ, Joseph JJ, Phan LM & DeStefano CB. 2022. CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges. Blood Lymphatics Cancer, 12:119-135.

Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, Malik S, Nath R, Anwer F, Cruz JC, Htut M, Karski EE, Lovelace W, Dillon M, Butz E, Ying W, Balakumaran A Kumar SK. 2023. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nature Medicine, Feb;29(2):422-429.

Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D,Senechal B, Bermudez VP, Pardon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Girat SA, Park JH, Usmani SZ, Riviere I, Brentjens RJ & Smith EL. 2022. GPRC5D-Targeted CAR T cells for Myeloma. New England Journal of Medicine, 387:119601206.

Dhodapkar M, Alsina M, Berdeja J, Patel K, Vij R, Leleu X, Truppel-Hartmann A, Basudhar D, Thompson E, Zheng X, Ananthakrishnan R, Favre-Kontula L, Greggio C, Sternas L & Siegal D. 2022. KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation. Blood, 140 (Supplement 1): 7441-7443.

Usmani S, Patel K, Hari P, Berdeja J, Alsina M, Vij R, Raje N, Leleu X, Dhodapkar M, Reshef R, Truppel-Hartmann A, Basudhar D, Thompson E, Zheng X, Ananthakrishnan R, Greggio C, Favre-Kontula L, Sternas L & San-Migel J. 2022. KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation. Blood, 140 (Supplement 1): 875-877.

Delforge M, Baz R, Cavo M, Callander NS, Ghobadi A, Rodriguez-Otero P, Mateos MV, Massaro M, Ding L, Patel P, Pittari G, Novick S, Giralt SA & Berdeja JG. 2020. KarMMA-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma. Blood, 136 (Supplement 1): 24-25.

Usmani SZ, Berdeja JG, Truppel-Hartmann A, Casadebaig ML, Wortman-Vayn H, Shelat SG, Novick S & Shah N. 2020. KarMMA-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma. Blood, 136 (Supplement 1): 18-19.

Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, WCJ van de Don N, Martin T, Suvannasankha A, De Braganza KC, Corsale C, Schecter JM, Varsos H, Deraedt W, Wang L, Vogel M, Roccia T, Xu X, Mistry P, Zudaire E, Akram M, Nesheiwat T, Pacaud L, Avivi I & San-Miguel J. 2023. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood, 141(3):219-230.

Dhakal B, Yong K, Harrison SJ, Mateos MV, Moreau P, van de Donk NWCJ, Sidana S, Popat R, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Li K, Zudaire E, Chen Y, Gilbert J, Bubuteishvili-Pacaud L, Patel N, San-Miguel J, Einsele H. 2023. First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. Journal of Clinical Oncology, 41(17-Supplement).

Published

2023-11-06

How to Cite

1.
Bhella S. Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape. Can Hematol Today [Internet]. 2023 Nov. 6 [cited 2024 Jun. 19];2(3):33-8. Available from: https://canadianhematologytoday.com/article/view/2-3-bhella

Issue

Section

Articles